Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction

NCT03986385 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Apatinib Capecitabine Oxaliplatin
DRUG: Capecitabine Oxaliplatin

Sponsor

Hebei Medical University